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Abstract
Background: Distal alveolar morphogenesis is marked by differentiation of alveolar type (AT)-II to AT-I cells that
give rise to the primary site of gas exchange, the alveolar/vascular interface. Endothelial-Monocyte Activating
Polypeptide (EMAP) II, an endogenous protein with anti-angiogenic properties, profoundly disrupts distal lung
neovascularization and alveolar formation during lung morphogenesis, and is robustly expressed in the dysplastic
alveolar regions of infants with Bronchopulmonary dysplasia. Determination as to whether EMAP II has a direct or
indirect affect on ATII®ATI trans-differentiation has not been explored.
Method: In a controlled nonvascular environment, an in vitro model of ATII®ATI cell trans-differentiation was
utilized to demonstrate the contribution that one vascular mediator has on distal epithelial cell differentiation.
Results: Here, we show that EMAP II significantly blocked ATII®ATI cell transdifferentiation by increasing cellular
apoptosis and inhibiting expression of ATI markers. Moreover, EMAP II-treated ATII cells displayed myofibroblast
characteristics, including elevated cellular proliferation, increased actin cytoskeleton stress fibers and Rho-GTPase
activity, and increased nuclear:cytoplasmic volume. However, EMAP II-treated cells did not express the
myofibroblast markers desmin or aSMA.
Conclusion: Our findings demonstrate that EMAP II interferes with ATII ® ATI transdifferentiation resulting in a
proliferating non-myofibroblast cell. These data identify the transdifferentiating alveolar cell as a possible target for
EMAP II’s induction of alveolar dysplasia.
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Introduction
Alveolar epithelial cells (AECs), located deep within the
lung, have a pivotal role in gas exchange by acting in
conjunction with the capillary bed to disperse oxygen
throughout the body. Disruption of the distal alveolar
lining of the lung through environmental or inflamma-
tory induced injury results in the destruction of func-
tional gas-exchanging alveolar type I (ATI) cells.
Independent of the initial etiology, pathologic progres-
sion of acute lung injury (ALI) is the same marked by
regions of scarring intermixed with alveolar damage,
dysfunctional vasculature, and fibro-proliferative lung
disease [1,2]. Within this process and essential to
regeneration of gas-exchanging epithelial cells to satisfy
the body’s oxygen demands, is the regrowth of AECs.
Recent studies suggest a paradigm shift in our under-
standing of distal lung repair. Although previously ATII
cells were identified as an endogenous progenitor cell
that gives rise only to gas-exchanging ATI cells, the abil-
ity of the ATII cell to function in a pluripotent manner
was recently recognized. In response to local factors
such as TGF-b expression, ATII cells can undergo an
epithelial to mesenchymal transdifferentiation (EMT) to
become myofibroblast [3,4]. Therefore, repopulation of
the distal alveoli with gas-exchanging ATI cells follow-
ing ALI is dependent on local growth factors that have
the capability of redirecting differentiating ATII cells to
myofibroblast thus contributing to the pathologic fibro-
proliferative lung disease.
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Endothelial Monocyte Activating Polypeptide II (EMAP
II). Although EMAP II’s impact on the pathologic pro-
gression of hypoplastic lung disease has been well docu-
mented, little is known regarding the mechanisms that
contribute to formation of the functional gas-exchanging
ATI cells [5,6]. EMAP II, located on the cell surface,
undergoes proteolytic cleavage to a mature ≈22-kDa
form (mEMAP II) [7-9] that functions as a potent anti-
angiogenic peptide [10,11]. Prevalent in early lung devel-
opment, its expression is inversely correlated to periods
of vascularization [12,13]. However excess amounts of
mEMAP II delivered in a recombinant form to a murine
allograft model of lung development profoundly disrupts
not only vascular formation, but strikingly inhibits
alveolar growth with a concomitant induction of distal
alveolar apoptosis [5]. Furthermore, EMAP II expression
is markedly increased in pathologic states associated
with lung dysplasia such as in the distal alveoli of infants
with Bronchopulmonary dysplasia (BPD) [6], LPS-
induced acute lung injury [14], and emphysema [15].
Due to EMAP II’s ability to inhibit distal alveoli forma-
tion and its elevation in disease processes where ATI
cells are compromised, our studies focused on one of
the properties associated with the regeneration of gas-
exchanging ATI cells, ATII ® ATI transdifferentiation.
We demonstrate that EMAP II inhibits ATII ® ATI dif-
ferentiation. Furthermore, while EMAP II increased
ATII cell apoptosis, there was also a concomitant
increase in cellular proliferation. Associated with the
increase in proliferation, F-actin bundles and Rho-
GTPase activity were markedly increased. However, con-
trary to previous reports where F-actin and elevated
Rho-GTPase activity is associated with EMT, EMAP II
treated cells did not express the myofibroblast markers
of desmin or aSMA. These studies indicate that EMAP
II directly interferes with ATII ® ATI transdifferentia-
tion resulting in a non-myofibroblast undifferentiated
cell, thus identifying the transdifferentiating cell as a
possible target for EMAP II’s induction of alveolar
dysplasia.
Materials and methods
Cells
Primary alveolar epithelial cell isolation and AEC monolayer
AT II cells were isolated from adult Sprague-Dawley male
rats (120-160 g) as previously described [16,17]. In brief,
lungs were disassociated with elastase (1.5-2.0 U/ml,
Worthington Biochemical, Freehold, NJ) and isolated
based on their differential adhesion properties to IgG
(Sigma, St. Louis, MO). Freshly isolated AT II cells were
plated in a minimal defined serum-free medium (MDSF),
( D M E M / F 1 21 : 1 ,S i g m aA l d r i c h ,S t .L o u i s ,M O )o n4 . 6 7
cm2 tissue culture-treated polycarbonate filter cups
(Transwell, Corning Incorporated, MA) in a humidified
5%CO2 incubator at 37°C. Cytospins of fresh cell isolates
indicated 85-90% ATII cell purity determined by immuno-
fluorescent staining for P180. Fibroblasts were selectively
removed from cultures with the addition of a 100 μg/ml
cis-OH-proline (Sigma Aldrich, St. Louis, MO) supple-
ment for the first 48 hours [18]. Some cultures were trea-
ted daily with either vehicle (control, PBS) or EMAP II (3
mcg/ml) beginning on day 0 through day 8, while some
cultures were treated for only the first 4 days of 8 treat-
ment days. Animals were treated in accordance with the
guidelines of and with the approval of the University of
Texas, Southwestern Medical Center Institutional Animal
Care and Use Committee.
Protein analysis
Western analysis
For Western analysis, cells were lysed in 50 mM Tris
pH 7.4, 0.9 N NaCl, 1% NP-40, and 0.01% NaN3, in the
presence of the protease inhibitors (aprotinin 20 μg/ml,
leupeptin 20 μg/ml, and pepstatin A 20 μg/ml), and
stored at -70°C. Homogenates were cleared by centrifu-
gation at 14,000 × g for 20 minutes, the protein concen-
tration determined by Bradford analysis (BioRad
Hercules, CA), and the samples normalized by protein
content. Equal amounts of protein were electrophoresed
on a 10% SDS-PAGE gel, transferred to nitrocellulose
membranes, blocked overnight in a casein-based block-
ing solution (Boehringer-Mannheim, Indianapolis, IN),
and probed with primary antibody followed by horserad-
ish-peroxidase-conjugateda n t i - m o u s e( J a c k s o nI m m u -
noResearch Laboratories, West Grove, PA) and anti-
rabbit IgG antibodies were purchased from Thermo
Scientific, Rockford, IL. Specific binding was detected
using a chemiluminescence substrate (Pierce, Rockford,
IL) and XAR-5 film (Eastman Kodak, Rochester, NY).
Quantitative analysis was accomplished using Quantity
O n eS o f t w a r ea n ds a m p l e sw e r en o r m a l i z e da g a i n s t
actin or tubulin.
Rho Kinase Assay
Active Rho Kinase was assessed using an EZ-Detect™
Rho Activation Kit (Pierce, Rockford, IL) based on Rho-
tekin Rho-binding domain. Protein was isolated accord-
ing to manufacture protocol, protein concentration
assessed, and Rho Kinase activity examined on equal
protein amounts using Western Blot analysis. GTP,
GDP, and unfractionated cell lysate were used as con-
trols. Semi-quantitative densitometry was carried out as
previously described [19].
Histological analysis
Immunofluorescence
Alveolar epithelial cell monolayers were rinsed with ice-
cold phosphate-buffered saline (PBS) twice and fixed in
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Page 2 of 114% paraformalderhyde overnight at 4 degree. Cells were
permeabilized in 0.1%Triton X-100, followed by block-
ing with CAS (Invitrogen, Carlsbad, CA) and exposed to
the primary antibody 1 hr [anti-b-catenin (Santa Cruz
Biotechnology,), anti-Ki67 (Abcam, Cambridge, MA),
anti-ZO-1(Invitrogen, Carlsbad, CA), anti-Lamellar body
P180 (Covance, Berkeley, CA), anti-AQP5 (Chemicon,
Temecula, CA), anti-fibronectin (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), anti-actin or anti-F-actin (Invitro-
gen,)] as per manufactures instructions. Following
washing with PBS, tissues were exposed to the appropri-
ate secondary Cy3 or AlexaFluor 488 fluorescent anti-
body (Chemicon, Temecula, CA and Molecular Probes
Invitrogen, Carlsbad, CA) for 1 hour. This was followed
by a six minute incubation with membrane permeable
DAPI (4’,6-Diamidino-2-phenyindole 5 mg/ml at 1:1,000
dilution, Invitrogen), rinsing with PBS and mounting.
TUNEL staining was performed using an ApoAlert
DNA Fragmentation Assay kit (Clontech, Mountain
View, CA) according to the manufacturer’s instructions.
Positive TUNEL staining (green staining) cells were
characterized as apoptotic cells and 10 randomly
selected microscopic fields in each group were used to
calculate the percentage of TUNEL positive cells. Simi-
larly positive Ki67 cells were examined in 10 randomly
selected fields. Importantly total cell number was calcu-
lated using DAPI (nuclear) counting in the same field
and the positive TUNEL or Ki67 cells were reported as
percent of cells present. The signal was viewed by fluor-
escent microscopy at the appropriate wavelength for the
secondary antibody on an IX81 Olympus microscope
and images captured with a Hamamatsu Orca digital
camera with a DSU spinning confocal unit using Slide-
book software.
Statistical analysis
Statistical analysis was performed using a Student’sT
test or ANOVA on the software PRISM 4.0 for MacIn-
tosh (GraphPad Software, Inc., San Diego, CA).
Results
EMAP II treatment mediates ATII ® ATI trans-
differentiation
Although angiogenesis is widely described as influencing
distal pulmonary morphogenesis, the molecular events
during vessel formation that drive pulmonary develop-
ment have not been determined. Previous studies have
shown that the anti-angiogenic protein EMAP II pro-
foundly disrupts alveolar-capillary growth and is highly
expressed in distal alveoli of hypoplastic lungs [5,6]. In a
controlled, nonvascular environment, we utilized an in
vitro model of ATII ® ATI cell trans-differentiation
[16,17,20] to demonstrate the contribution that one
vascular mediator has on distal epithelial cell
differentiation. Freshly isolated ATII cells from disso-
ciated rat lungs were subjected to IgG panning and
determined to be 85-90% pure by lamellar body expres-
sion (P180, Figure 1A), were plated on polycarbonate fil-
ters in serum-free medium. Cells were exposed to either
vehicle or the anti-angiogenic protein EMAP II on days
0-8 and examined for ATI markers. As can be seen in
Figure 1B, ATII cells gradually flattened, acquired an
epithelial like polygonal shape, and express the ATI
water channel membrane protein Aquaporin 5 (AQP5)
on day eight. In contrast, ATII cells treated with EMAP
II exhibited a marked reduction in AQP5 protein as
determined by immunofluorescence and confirmed by
Western Analysis (Figure 1C, D, F, G, Student’s T-test p
= 0.02) (n = 5 on separate occasions) as compared to
control (Figure 1B, D, F, G). RAGE (Receptor for
Advanced Glycation Endproducts), a second AT1 mar-
ker was also significantly reduced (D, G, n = 5 on sepa-
rate occasions). Importantly, no surfactant protein C
(SPC) expression was noted in cells at day 8 in either
the control or EMAP II cells (Figure 1E) suggesting that
in all conditions at day 8 the cells no longer express the
ATII protein SPC. Studies over 8 days where cells were
treated with EMAP II for only the first 4 days and then
EMAP II was replaced with vehicle for the last 4 days
prior to harvest, these cells demonstrated a 40% reduc-
tion in AQP5 and RAGE protein expression (data not
shown). These data suggest that EMAP II inhibits
ATII®ATI trans-differentiation. We next explored
alternative pathways of ATII trans-differentiation.
EMAP II induces apoptosis in trans-differentiating alveolar
cells
Previous studies have shown that EMAP II inhibits dis-
tal ATII and ATI cells during lung morphogenesis [5].
In addition to distal lung lacking ATII and ATI markers,
EMAP II induced apoptosis in the distal alveoli of the
developing lung and in vitro lung co-culture epithelial
cysts [5,21]. One response of alveolar epithelial cells to
injury is apoptosis [3]. We performed TUNEL analysis
on trans-differentiating ATII ® ATI cells to determine
if EMAP II had the ability to induce apoptosis in differ-
entiating alveolar cells. Consistent with previous in vivo
and in vitro lung co-culture [5,21], isolated trans-differ-
entiating ATII cells had a marked increase in TUNEL
positive cells in the presence of EMAP II treatment (Fig-
ure 2C-E, p < 0.01, Student’s T-test) (n = 11 high pow-
ered field, performed on 3 different occasions) as
compared to control (Figure 2A, B, E). Apoptosis was
confirmed by PARP-1 cleavage (Figure 2F, G, p < 0.05,
One-way Anova with Post Hoc Tukey’st e s t ) .N o t a b l y ,
only portions of the total cell population were under-
going apoptosis. We next explored alternative ATII
trans-differentiating pathways.
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Page 3 of 11Figure 1 EMAP II inhibits AT II ® AT1 transdifferentiation. Aquaporin 5 (AQP5) expression was examined 8 days following isolation of AT II
cells using IgG panning (A - p180 lamellar body positive, cy3; G - surfactant protein C positive, day 0). Immunofluorescence and Western blot
analysis for AQP5 indicated that AT II cells transdifferentiate into AT1 cells over an eight-day period (B - FITC, D, E). AT II cells subjected to EMAP
II for 8 days in culture have a marked reduction in AQP5 and RAGE expression (C, D, F, G) as compared to control (B, D, F, G). Neither cell
population had surfactant protein C (SPC) expression after 8 days in culture (E). DAPI denotes nuclear staining. Scale bar = A - 37.5 μ, B-D-25 μ.
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In spite of the fact that there was a marked increase in
apoptosis in the EMAP II treated cells, there was no dif-
ference in total cell counts between EMAP II and Con-
trol treated cells (Figure 2H). One way to maintain an
equivalent cell number in the presence of on going cell
death is cellular proliferation. Although trans-differen-
tiating ATII ® ATI cells are not known to proliferate
[22], we examined whether the equivalent cell numbers
between groups was due to cellular proliferation. Histo-
logical analysis of the cell proliferative marker Ki67 in
10 high powered fields on three different occasions indi-
cates that trans-differentiating ATII cells treated with
EMAP II have a significant increase in proliferation on
days 4 and 8 in culture (Figure 3C, D, I, p < 0.01, Stu-
dent’s T-test, n = 10 high powered fields) as compared
to control (Figure 3A, B, I). Importantly, EMAP II
induced cellular proliferation was limited to non-
myofibroblast type cells as the Ki67 cells did not co-
express F-actin bundles nor a smooth muscle actin (Fig-
ure 3G, H, * - aSMA and F-actin bundles, arrow - Ki67
positive cells). In conjunction with the increase in prolif-
eration, we examined the cellular distribution of a mem-
ber of the adherens junction proteins, b-catenin which
is responsible for stopping epithelial cell division
through transmission of a contact inhibition signal [23].
EMAP II treated cells demonstrated a marked loss of
the cobblestone appearance of epithelial like polygonal
shaped cells (Figure 4C, D), a decrease in b-catenin
expression at day 4 (Figure 4E, F) (p = 0.02, Student’s
T-test, n = 4 on 4 separate occasions), and an increase
in b-catenin membrane ruffling (Figure 4C-D, arrows)
as compared to control (Figure 4A, B, E, F) (p < 0.01,
ANOVA, n = 3 on separate occasions). Zona occludens
(data not shown) and E-cadherin expression (Figure 4I,
J, One-way ANOVA with Tukey’s post-hoc test) was
Figure 2 Apoptosis is increased by EMAP II in transdifferentiating cells. Isolated, AT II cells were examined at days 4 and 8 for apoptosis
using an immunofluorescent TUNEL assay. Cells treated with EMAP II had a marked increase in apoptotic cells at days 4 and 8 (C, D, and E) as
compared to control (A, B, and E). Western blot analysis of the caspase cleaved PARP-1 indicated a marked increase in PARP-1 cleavage in EMAP
II treated cells as compared to control (F, G). DAPI denotes nuclear staining. Despite an increase in apoptosis, total cell number remained
unchanged between control and EMAP II treated cells (H). Scale bar = 37.5 μ.
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separate occasions). In addition to a loss of cobblestone
polygonal shape, the cell nuclear volume and nuclear:
cytoplasmic ratio were noted to be markedly increased
in trans-differentiating AT II cells treated with EMAP II
(Figure 4G, H) as compared to control (p < 0.01, One-
way ANOVA with Tukey’s post-hoc test, n = 7, repre-
sentative of 4 separate occasions).
F-actin bundles and Rho-Kinase activity are increased by
EMAP II while aSMA and desmin activity are suppressed
As epithelial-mesenchymal cell transition (EMT) is asso-
ciated with active membrane ruffling of bound b-catenin
[24,25], increases in nuclear:cytoplasmic volume [26],
and loss of the cobblestone appearance of polygonal
shaped cells [27], we examined EMAP II treated cells for
signs of EMT. Actin cytoskeleton in control cells demon-
strated cortical bands at days 4 and 8 (Figure 5A, B,
Figure 5E, F, arrows). In contrast, the F actin in EMAP II
treated cells displayed actin bundles at all time points
consistent with the cytoskeletal structure found in myofi-
broblast (Figure 5C, D, G, H, stars). As F-actin deposition
and cytoskeletal rearrangement is a downstream marker
of Rho-GTPase activity, Rho-GTPase activity was exam-
ined. Further supporting EMT of cells into a myofibro-
blast phenotype, EMAP II treatment markedly increased
Rho-GTPase activity as compared to control (Figure 6A,
B, One-way ANOVA with Tukey’s post-hoc test, 6A, C-
Total RhoA expression was not significantly different
between groups, One-way ANOVA with Tukey’sp o s t -
hoc test). However, Western blot analysis indicates that
EMAP II suppresses expression of the myofibroblast
markers a smooth muscle actin (SMA) (Figure 6D, E) (p
< 0.002, Student’s T-test) and desmin (Figure 6D, F, Stu-
dent’s T-test) (n = 3 on different occasions, day 4 analysis
showed no expression of aS M Ao rd e s m i ni ne i t h e r
treatment group). In addition, the extracellular matrix
protein FN was decreased in cells treated with EMAP II
(Figure 6G, H, NS, n = 4 on different occasions, One-way
ANOVA with Tukey’s post-hoc test). Taken together
Figure 3 EMAP II increases proliferation in non-myofibroblast cells. Proliferation was assessed using immunofluorescence for Ki67 in
isolated AT II cells in culture at days 4 and 8. EMAP II significantly increased proliferation at days 4 and 8 (C, D, I) as compared to control (A, B,
I). Co-localization of Ki67 with aSMA (E-control, G-EMAP II treated) and F actin (F-control, H-EMAP II treated) indicates that the proliferating cell
population was negative for myofibroblast markers. DAPI denotes nuclear staining. Scale bar = 37.5 μ (A-D), 25 μ (E-H).
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AT II cells from becoming AT1 cells or myofibroblast
resulting in a cell either undergoing apoptosis or assum-
ing an undifferentiated cell phenotype.
Discussion
The mature form of EMAP II (mEMAP II) has been
shown to induce distal alveolar dysplasia, however the
mechanism associated with its inhibition of alveoli is
poorly understood. What is clear is that in addition to a
marked reduction in vessel formation, there is a conco-
mitant reduction in alveolar cells. This raised the possi-
bility that in addition to EMAP II’s inhibition of
vasculature having an indirect suppressor effect on
alveolar cells, that EMAP II might indeed directly inhibit
ATI cell formation. Examination of the cell population
Figure 4 Decreased Beta-catenin expression corresponds with marked membrane ruffling, increase in nuclear size and nuclear:
cytoplasmic ratio in EMAP II treated cells. Immunofluorescent staining of AT II cellular membranes indicate that transdifferentiating AT II cells
develop a cobblestone appearance of epithelial like polygonal shaped cells (A, B). Transdifferentiating AT II cells treated with EMAP II lack the
polygonal shape (C, D), exhibit membrane ruffling (arrows, D), and have decreased b-catenin expression of at day 4 (E, F). In addition, EMAP II
treated cells demonstrated a larger nuclear size and nuclear:cytoplasmic ratio as compared to controls (G, H). DAPI denotes nuclear staining. E-
cadherin expression was not significantly different between EMAP II and control cells (I, J) Scale bar = 25 μ.
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Page 7 of 11Figure 5 EMAP II inhibited actin cortical bands and increased actin bundles in transdifferentiating AT II cells. F-actin at days 4 and 8 is
distributed in cortical bands in differentiating AT II cells (arrows, A, B and E, F, FITC). Transdifferentiating cells treated with EMAP II lack cortical
bands and demonstrate marked increase in actin bundles (stars, C, D and G, H, FITC). G-actin is revealed with cy3 and DAPI denotes nuclear
staining. Scale bar = 25 μ.
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mEMAP II blocks transdifferentiation of the ATII cells
into ATI cells in an avascular model. Furthermore, we
determined that ATII cells exposed to EMAP II either
underwent apoptosis or expressed several phenotypic
markers of EMT. However, in contrast to previous stu-
dies where cells express markers of EMT, EMAP II trea-
ted ATII cells did not express the myofibroblast markers
aSMA or desmin. These findings indicate that in a non-
vascular system, EMAP II alters ATII ® ATI transdif-
ferentiation resulting in the formation of a non-myofi-
broblast undifferentiated cell population. These findings
support a role for mEMAP II that reaches beyond the
endothelium in distal alveolar differentiation.
Cell fate is influenced by growth factors and deter-
mines the regeneration of functional air-exchanging
alveolar cells or myofibroblastic cells following lung
injury. Previous observations showed that ATII transdif-
ferentiation does occur in vitro and leads to one of
three distinct pathways which results in ATI, myofibro-
blast, or apoptotic cell populations [3,4]. A cellular
model affords a unique opportunity to explore the
mechanisms influencing cellular fate. Previous studies
s u g g e s tt h a tt h en a t u r a l l yoccurring protein EMAP II
may have a role in distal lung repair as EMAP II is
highly expressed in the distal lung in patients with BPD
[6], emphysema [15], and following LPS induced lung
injury [14]. In these circumstances of disease and lung
damage, such as that seen in smoke induced lung
damage, EMAP II plays a significant and leading role
[15]. Further determination on how EMAP II mechanis-
tically influences distal alveolar differentiation versus
death are essential in being able to develop therapeutic
strategies to combat lung damage. However, it is not
known whether the elevated levels of EMAP II influence
distal alveolar regeneration processes. Importantly, in
line with those seen when other angiogenic mediators
[28-32], exogenous mEMAP II inhibited vascular and
distal alveolar cell formation without clarifying whether
its affect was through a direct influence on alveolar cells
or an indirect consequence of the lack of vasculature.
While EMAP II is not known to be involved in
ATII®ATI transdifferentiation, in these avascular stu-
dies we show that mEMAP II directly mediates in vitro
ATII cell differentiation. Specifically in conjunction with
al o s so fA T I Ia n dA T Ic e l lm a r k e r s ,t h e r ew a sa n
increase in apoptosis, consistent with our distal alveolar
findings using a fetal lung explant model [5]. Interest-
ingly, EMAP II induced apoptosis in a limited cell popu-
lation. This is similar to our previous findings in
endothelial cells where EMAP II induced apoptosis only
in the actively dividing endothelial cell population [10].
As fibronectin levels were decreased in the differentiat-
ing ATII cells and fibronectin has been shown to
enhance pulmonary ATII epithelial cytoskeleton and
tight junction organization [33], we speculate that the
decrease in fibronectin results in a reduction in tight
junction organization making some cells vulnerable to
apoptosis. These mechanistic questions are the focus of
our ongoing studies. Taken together, these findings sug-
gest that EMAP II has a greater role in lung that
extends beyond the endothelium.
In contrast to the influence of other growth factors
such as TGFb induced ATII® myofibroblast transdiffer-
entiation [3,4], EMAP II-treatment results in the emer-
gence of an as to yet unidentified cell population. We
thus explored a potential alternative transdifferentiation
pathway underlying EMAP II associated loss of ATI cell
markers. While this cell population has some of the
hallmark characteristics of a cell undergoing TGFb
induced EMT, increased nuclear/cytoplasmic volume,
changes in nuclear shape [34], loss of cobblestone
appearance [27], active ruffling of b-catenin, elevation of
rho kinase activity [25,35] and actin cytoskeleton
dynamics consistent with myofibroblast morphology, the
resulting cell population lacks expression of the classic
myofibroblast biomarkers aSMA and desmin [36,37].
Interestingly, despite the structural similarities between
EMAP II treated cells and those undergoing EMT,
Figure 6 EMAP II increases Rho-GTPase expression while aSMA
and desmin expression are decreased in transdifferentiating
AT II cells. Rho-GTPase activity was assessed in AT II cells in culture
at 0, 4, and 8 days using a Rhotekin RBD probe to isolate active
GTP-Rho. EMAP II treatment increased Rho-GTPase activity as
compared to controls (A, B). However total Rho A levels normalized
to actin in ATII cells in cultures treated with EMAP II were
unchanged as compared to control (A, C). After 8 days in culture,
aSMA actin levels were markedly decreased as compared to control
(D, E) and desmin was minimally expressed in EMAP II treated cells
(D, F). Protein expression was normalized to actin loading controls
and whole lung lysate (WLL) was used as an addition loading
control (D). Fibronectin expression (FN) was reduced following
EMAP II treatment (G, H, normalized to alpha-tubulin loading
control).
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not shown). These findings suggest that EMAP II
induces the emergence of a cell population whose role
is yet to identified. While not previously identified in
alveolar epithelial cell transdifferentiation, there is prece-
dence for intermediate cell populations that undergo
‘partial EMT’ to exist during epithelial trans differentia-
tion [38]. The role of EMAP II in epithelial transdiffer-
entiation is the focus of our ongoing studies.
Proteolytic cleavage from the cell surface to a ≈ 22-
kDa form (mEMAP II) [39], endogenous EMAP II func-
tions as a potent anti-angiogenic peptide in both normal
physiologic lung development [5,12,21] and pathologic
tumor regulation [10,11,40-42]. A fundamental role in
lung development is supported by EMAP II expression
being inversely correlated to periods of vascularization
[12,13] and presentation of recombinant EMAP II in a
murine allograft model of lung development profoundly
disrupts alveolar-capillary growth [5]. Furthermore the
impact of EMAP II on the pathologic progression of
lung disease has been well established while the
mechanisms of how EMAP II facilitates distal lung dys-
plasia are poorly understood. Mechanistically, EMAP II
functions by inhibiting binding of the a5b1i n t e g r i nt o
its extracellular ligand fibronectin. This inhibition
results in delayed cell spreading and the disassembly of
the cytoskeleton architecture of actin fiber networks,
and fibronectin matrix [42,43]. Previous studies in
Xenopus models support a role for a5b1 integrin regu-
lation of spreading in non-pulmonary epithelial transdif-
ferentiation. During Xenopus gastrulation, epithelial cell
spreading is dependent on the cellular engagement of
the fibronectin fibrils via the cells a5b1 integrin recep-
tor and this initiates spatial cues that assign cellular
polarity and differentiation [44,45]. Once fibronectin is
engaged to the a5b1 receptor, this facilitates a cascade
of events resulting in the formation of the complex 3-D
mesh like fibrils in the extracellular space known as
fibrillogenesis. In ATII cells a role for fibronectin has
been identified. Immortalized pulmonary epithelial cells
demonstrate adhesion affinity to fibronectin (rat type II
cell lines - LM5 and alveolar cell carcinoma cells -
A549) [46] while fibronectin enhances pulmonary ATII
epithelial cytoskeleton actin and tight junction organiza-
tion [33]. Analysis of EMAP II’s ability to alter actin
cytoskeletal organization suggests that there is a marked
increase in actin bundles despite a significant decline in
total cell fibronectin (Figure 6) and no change in a5b1
integrin expression. This finding is inconsistent with
our previous observations in endothelial cells where
EMAP II inhibits actin cytoskeleton formation [43].
What is not clear is whether epithelial transdifferentia-
tion is dependent on specific extracellular matrix com-
ponents and whether or not EMAP II alters these
factors. This area of investigation is part of our ongoing
studies.
Conclusion
In conclusion, our studies indicate that the angiogenic
mediator EMAP II influences ATII®ATI trans-differen-
tiation. Understanding the role that this EMAP II has in
the regulation of distal alveolar development and alveo-
lar cell regeneration can allow further insight into the
repair process that gives rise to an essential and func-
tional gas-exchanging alveolar type I.
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